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Purpose 




Medline, Embase, Biosis (to November 2005), Science Citation Index (to December 
2005) and The Cochrane Library (Issue 4 2005) were searched.  Studies assessing 
candidate screening tests for detecting OAG in people over 40 years of age that 
reported true and false positives and negatives were included.  Meta-analysis was 
undertaken using the hierarchical summary receiver operating characteristic model.   
 
Results 
Forty studies enrolling over 48,000 people reported nine tests.  Most tests were 
reported by only a few studies. Frequency Doubling Technology (FDT) (C-20-1) was 
significantly more sensitive than ophthalmoscopy (30, 95% credible interval (CrI) 0 to 
62) and Goldmann applanation tonometry, (GAT), (45, 95% CrI 17 to 68), while 
threshold standard automated perimetry (SAP) and Heidelberg Retinal Tomograph 
(HRT II) were both more sensitive than GAT (41, 95% CrI 14 to 64 and 39, 95% CrI 3 
to 64 respectively).  GAT was more specific than both FDT C-20-5 (19, 95% CrI 0 to 
53) and threshold SAP (14, 95% CrI 1 to 37).  Judging performance by diagnostic odds 
ratio, FDT, Oculokinetic perimetry and HRT II are promising tests. Ophthalmoscopy, 
SAP, retinal photography and GAT had relatively poor performance as single tests.  
These findings are based on heterogeneous data of limited quality and as such 




No test or group of tests were clearly superior as glaucoma screening tests.  Further 
research is required to evaluate the comparative accuracy of the most promising 




Glaucoma describes a group of eye diseases in which there is progressive damage to 
the optic nerve, leading to impaired vision and in some cases blindness if untreated.   
Glaucoma is the leading cause of irreversible blindness worldwide,1,2 with open 
angle glaucoma (OAG) the most common form.1  Late detection is a major risk factor 
for blindness;1,3-5 it is estimated from population surveys that in developed countries, 
more than 50% of prevalent OAG is undetected,6 and this estimate is likely to be 
higher in developing countries. Recent evidence suggests that treatment is effective 
at delaying progression,7,8 thus population based screening of OAG is under 
consideration.6,9-11  For screening to be considered several criteria need to be met 
regarding the condition, the test and the screening programme.9  
 Tests for glaucoma involve an assessment of structural changes at the optic 
nerve head, functional visual loss by visual field testing, and the level of the 
intraocular pressure (IOP).  There are many potential tests or combinations of tests 
for detecting glaucoma, however to date no single test or combination of tests has 
been identified as an optimal screening ‘test’ for glaucoma.   
The aim of this study was to assess the comparative accuracy of candidate 
screening tests.  





Highly sensitive electronic searches, using both controlled vocabulary and free text 
terms, were undertaken.  We searched the following electronic databases: Medline 
(1966 – November Week 3 2005), Medline In Process (23 February and 6 December 
2005), Embase (1980 – 2005 Week 49), Science Citation Index (1981 – 3 December 
2005), Biosis (1985 – 30 November 2005) and Cochrane Central Register of Controlled 
Trials (CENTRAL) (The Cochrane Library, Issue 4 2005).  In addition full text 
electronic searches of the American Journal of Ophthalmology (1998 – November 
2005), Ophthalmology (1998 – November 2005), British Journal of Ophthalmology 
(1998 – November 2005), Investigative Ophthalmology & Visual Science (1998 – 
November 2005) and the Journal of Glaucoma (2001 – November 2005) were 
undertaken.  Searches were restricted to English language publications.  The 
reference lists of included studies were scanned to identify additional potentially 
relevant reports.  Full details of the sources searched and search strategies used are 
available elsewhere6 or can be obtained by contacting the authors.  
 
Inclusion and Exclusion Criteria 
We included studies that assessed the accuracy of tests for detecting OAG in people 
over 40 years of age who were likely to be representative of a screening situation (i.e. 
no selection and no previous tests have been done) or of a glaucoma suspect 
population (i.e. patients identified from prior testing as possibly having glaucoma or 
having e.g., high IOP, or another risk factor for glaucoma but with an unconfirmed 
diagnosis)   Both randomised (where participants were randomised to one or more 
tests) and observational (both cohort and case-control) studies were included.    The 
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reference standard was either confirmed OAG on follow-up or ophthalmologist-
diagnosed OAG as reported by the study.  This latter reference standard required a 
clinical judgement by an ophthalmologist including an evaluation of the optic nerve 
and a measure of visual function.  In addition the study had to either report or allow 
the calculation of true and false positives and negatives.   
Non-English language reports were excluded, as were conference abstracts.  
Case reports and studies investigating technical aspects of a test were excluded.  
Case-control studies where the control group consisted of people with no ocular 
disease or specifically excluded people with other ocular disease, so that the 
spectrum of disease and non-disease was unlike that to be encountered in a screening 
situation, were also excluded.  The spectrum of disease expected would be similar to 
the spectrum of the disease of the general population (e.g., more patients with mild 
glaucoma, less patients with severe glaucoma). 
The candidate tests fell within the three broad categories of (a) structure 
(ophthalmoscopy; optic disc photography; retinal nerve fibre layer (RNFL) 
photography; Heidelberg retinal tomography (HRT) version II; GDx VCC retinal 
nerve fibre layer (RNFL) analyser; optical coherence tomography (OCT); retinal 
thickness analyser (RTA)), (b) function (oculokinetic perimetry (OKP); white-on-
white standard automated perimetry (SAP) including suprathreshold and threshold; 
short wave-length automated perimetry (SWAP); frequency doubling technology 
(FDT); motion detection perimetry (MDP)) and (c) IOP (Goldmann applanation 
tonometry (GAT); non contact tonometry (NCT); Tonopen). 
 
Data Abstraction and Quality Assessment 
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Two reviewers undertook single data extraction of the included studies.  In the event 
of any uncertainty, the other reviewer provided advice and validated the data 
extraction. 
Two reviewers independently assessed the quality of the included studies 
using a version of QUADAS adapted for assessing reports of the accuracy of 
screening tests for OAG.  QUADAS is a quality assessment tool for use in systematic 
reviews of diagnostic studies.12  Disagreements were resolved by consensus or 
arbitration by a third reviewer.  A ‘higher quality study’ was considered to be one 
that was checked ‘yes’ to questions 1 (patient spectrum representative), 3 and 4 
(partial and differential verification bias avoided) and 6 and 7 (test review bias and 
diagnostic review bias avoided) of the adapted QUADAS checklist. 
 
Statistical Methods 
After data extraction a ‘common’ (most frequently reported) cutoff for each test was 
selected following discussion by two ophthalmologists (JB, RS).  Summary receiver 
operating characteristic (SROC) curves were produced for each test where two or 
more studies reported estimates of sensitivity and specificity at the common cutoff.  
Meta-analysis models were fitted using the hierarchical summary receiver operating 
characteristic (HSROC) model13 in WinBUGS 1.4.14  Normally distributed random 
effects were assumed with non-informative uniform priors.  No adjustment was 
made for the correlation between results from paired studies, as the level of 
information required is rarely reported.  Summary sensitivity, specificity and 
diagnostic odds ratios (DORs) at the operating point were reported for each model as 
median and 95% credible interval (CrI).  A DOR is a single indicator of test 
performance and is the ratio of the odds of testing positive in those with the disease 
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relative to the odds of testing positive in those without the disease.15 It can be 
calculated from the sensitivity and specificity: 
DOR = (sensitivity /(1-sensitvity))/((1-specificity)/specificity) 
 Credible intervals are the Bayesian equivalent of confidence intervals.  A 
simplified model, which assumed a symmetrical ROC shape, was used where limited 
data caused convergence problems under the full model.  Sensitivity analysis was 
undertaken by examining separately the results of the higher quality studies, using 
HSROC analysis where more than one higher quality study reported the same test.   
Comparisons between tests were made in two ways.  First, studies which 
directly compared participants who either received all tests or were randomised to 
different tests were identified, and the direct comparisons inspected.  Secondly, an 
indirect comparison between tests, for all tests reported by two or more studies were 
modelled together in a single HSROC model to formally compare test performance.  
Pair-wise differences in sensitivity and specificity between tests were assessed from 





Figure 1 shows the flow of studies through the review.  Out of a total of 5918 
titles/abstracts screened, 877 potentially relevant full text articles were obtained, 
with 40 studies, published in 46 reports, meeting the inclusion criteria.  
 
Study Characteristics and Methodological Quality 
The characteristics of the included studies are shown in Table 1.  Twenty studies 
were population-based and representative of a screening setting16-39  while 20 studies 
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were considered representative of a glaucoma-suspect population referred from 
primary care, of which eight were cohort studies40-47 and 12 were case-control 
studies.48-61 Seven studies18,34,40,43,44,48,58 used the first and best reference standard of 
OAG confirmed on longitudinal follow-up while the remainder used 
ophthalmologist-diagnosed OAG.  
The 40 studies enrolled over 48,000 people, with over 39,000 included in the 
analysis.  The studies took place from 1963 to 2004.  In 26 studies reporting 
participant gender, 51% were women. The median (range) age of participants across 
studies was 60.5 years (13 to 97 years).  The reports included a number of major 
population-based prevalence surveys, such as the Baltimore Eye Survey,25,31 the Blue 
Mountains Eye Study,23 the Crete, Greece Glaucoma Study,27 the Dalby Population 
Survey,17 the Egna-Neumarkt Study,18 the Framingham Eye Study,43 the Glaucoma 
Screening Study (GLASS),24,26 the Groningen Longitudinal Glaucoma Study,53,54,59 the 
Rhondda Valley Study,22 the Rotterdam Study,38 the Segovia Study16 and the Visual 
Impairment Project.37  
The included studies reported the following tests: ophthalmoscopy (seven 
studies); optic disc photography (six studies); retinal nerve fibre layer (RNFL) 
photography (four studies); Heidelberg retinal tomograph (HRT) II (three studies); 
oculokinetic perimetry (OKP) (four studies); standard automated perimetry (SAP) 
(14 studies); frequency doubling technology (FDT) (eight studies); Goldmann 
applanation tonometry (GAT) (nine studies); non contact tonometry (NCT) (one 
study).  No reports of GDx VCC, OCT, RTA, SWAP, MDP or Tonopen were 
identified that met our inclusion criteria.   
Figure 2 summarises the results of the quality assessment for the 40 included 
studies.  Study quality was variable, only eight studies20,21,30,34,38,39,45,46 met the 
specified criteria for higher quality studies.     
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Quantitative Data Synthesis 
 
• Individual tests 
The sensitivity and specificity of the individual tests included in the HSROC meta-
analysis models are shown in Figure 3 and Appendix 1, which also includes DORs.   
DORs ranged from 10 for FDT C-20-5 to 181 for FDT C-20-1, with higher DORs 
indicating a better ability to differentiate between disease and non-diseased. There 
was statistical heterogeneity (variability in outcome beyond what would be expected 
by chance) across studies for most tests.  Ophthalmoscopy, retinal photography 
(optic disc photography and RNFL photography), GAT, standard automated 
perimetry (threshold and suprathreshold)  and FDT C20-5  were all relatively poorly 
performing tests based on lower DORs (range 10-30).  
Eight studies met the criteria for higher quality studies, including six population-
based studies and two cohort studies, and test accuracy data are detailed in Table 2.  
For both SAP threshold and FDT C-20-5, higher quality studies reported lower 
values for both sensitivity and specificity when compared with all studies, while two 
FDT C-20-5 studies not meeting the criteria for higher quality reported very high 
sensitivity values (98% and 100% respectively).  For optic disc photography, 
compared with all studies, the higher quality studies reported similar sensitivity 
(74% versus 73%) but lower specificity (82% versus 89%).  For HRT II, compared with 
all studies, the higher quality studies reported higher sensitivity (93% versus 86%) 
but slightly lower specificity (85% versus 89%). 
Seven studies reported test accuracy in different stages of glaucoma.24,51,52,54,55,60,61  
Of those reporting the same tests for different stages of glaucoma, Ieong and 
colleagues55 reported a sensitivity of 72% for SAP (suprathreshold) for early stage 
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glaucoma while Enger and colleagues51 and Katz and colleagues24 both reported a 
sensitivity of 97% for SAP (threshold) for early/moderate stage glaucoma.  
 
• Studies directly comparing tests 
Six studies directly compared two or more of the following tests for detection of 
OAG: optic disc photography, HRT II, SAP, FDT, GAT.23,30,34,36,46,55  Table 3 shows the 
common cut-off selected, sensitivity, specificity, DORs and relative DORs for these 
studies.  In each study SAP (either suprathreshold or threshold) was included as a 
comparator.  DORs for the tests ranged from 4 for SAP threshold46 to 75 for HRT II30 
(Table 3).  In terms of relative DORs, compared with SAP, GAT performed better in 
one study36 but worse in another23 (statistically significant), HRT II performed better 
than SAP in one study30 (statistically significant) but worse in another,55 FDT C-20-530 
and FDT C-20 matrix46 performed better than SAP, while optic disc photography34 
showed a broadly similar performance.   
 
• Indirect comparisons in a single HSROC model 
The results of the indirect comparisons in a single HSROC model are shown in Table 
4.  From the large number of comparisons undertaken, six showed a statistically 
significant difference between tests (four in terms of sensitivity and two in terms of 
specificity).  There was evidence that, at the common cut-off, FDT C-20-1 was 
significantly more sensitive than both ophthalmoscopy (30, 95% CrI 0 to 62) and GAT 
(45, 95% CrI 17 to 68), and that both SAP threshold (41, 95% CrI 14 to 64) and HRT II 
(39, 95% CrI 3 to 64) were significantly more sensitive than GAT.  There was also 
evidence that GAT was significantly more specific than both FDT C-20-5 (19, 95% CrI 
0 to 53) and SAP threshold (14, 95% CrI 1 to 37).  Other differences in accuracy 
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between tests may well exist which could not be detected due to the high level of 
uncertainty.  The wide credible intervals reflected the small number of studies 
reporting each test and the generally high level of heterogeneity.  Due to the 
imprecision in the estimates, no test (or even a group of tests) was clearly more 
accurate, based upon a 5% significance level.  Further analysis, at 10% and 20% levels 
of significance, identified additional statistically significant comparisons (Table 4).  
For example, in terms of sensitivity, at a 10% significance level FDT C-20-1 was better 
than SAP suprathreshold and at a 20% level better than optic disc photography, 
RNFL photography and FDT C-20-5.  OKP was better than GAT at a 10% level and 
HRT II better than ophthalmoscopy at a 20% level.  In terms of specificity, at a 20% 
level FDT C-20-1 was better than SAP threshold and FDT C-20-5.        
 
Discussion 
To our knowledge, this is the first systematic review of screening and diagnostic tests 
in glaucoma and includes 40 studies enrolling over 48,000 people and reporting nine 
tests.  Most tests were reported by only a few, mostly heterogeneous, studies.  The 
included studies reported tests of structure (ophthalmoscopy; optic disc 
photography, RNFL photography, HRT II), visual function (FDT, OKP, SAP) and 
IOP (GAT, NCT).  Other tests were considered, including those of structure (GDx 
VCC, OCT, RTA), visual function (SWAP; MDP), or using Tonopen to measure IOP.  
However, no studies using these tests met our inclusion criteria in terms of reporting 
of test accuracy outcomes.  
A systematic review of test accuracy is unlikely to identify the best test but 
can identify more promising tests. It is difficult to rank tests on paired values of 
sensitivity and specificity, as a highly specific test may be associated with a low 
sensitivity and vice versa. The choice of test depends on the importance of the trade 
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off between missed cases, and false positives. OAG affects an estimated 2% of the 
adult population; a test of low specificity would be likely to overburden a health 
service with people who do not have glaucoma and cause unnecessary anxiety for a 
many individuals, equally a test of low sensitivity would miss treatable disease 
which might be unacceptable to society.  The DOR, a single measure of test accuracy, 
is a useful measure for comparing accuracy of several tests in a meta-analysis.15 
Based on a DOR ≥50 , FDT C-20-1 and OKP (both tests of visual function) and HRT II 
(a test of glaucomatous optic neuropathy) merit further evaluation as to their 
performance as screening tests for glaucoma. It should be noted that these findings 
are relevant to the common cutoff point selected for each test; selection was based on 
the most frequently reported cut-off and when several cut-offs were reported the cut-
off most likely to represent early glaucoma.  Furthermore these findings are based on 
heterogeneous data of limited quality and as such are associated with considerable 
uncertainty. 
 Methods of meta-analysis of diagnostic accuracy which combine studies 
where both sensitivity and specificity vary have been available since 1990 and are 
continuing to evolve.13,62-66 These methods are based on the idea of a trade-off 
relationship between sensitivity and specificity, as occurs when studies vary in 
threshold, and aim to estimate the shape and position of the underlying Receiver 
Operating Curve.  From the estimate of this curve it is possible to identify “operating 
points”.  The approach adopted in our review identifies the average operating point 
for each test, and makes comparisons between them, based upon those studies 
reporting each test that share a common cut point.  The Cochrane Collaboration are 
commencing publication of systematic reviews of diagnostic test accuracy and the 
analytical approach we have followed is the one that they are recommending.67  
Estimation of a summary point specific to a test being used at a common threshold 
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obtains the best estimate of test accuracy in parameters that are clinically meaningful.  
The trade-off between sensitivity and specificity is important in judging the 
performance of a test and is best depicted by a ROC curve across different cutoff 
points.  However, the included studies did not usually provide information across 
the whole range of cutoff points to allow such analyses to be undertaken.   
We used a Bayesian Hierarchical SROC model as standard methods for meta-
analysis do not address the issue of threshold effect and are therefore not 
appropriate.68  A number of different levels of analyses were undertaken, including 
an analysis where all tests were modelled simultaneously using this Bayesian 
approach.  This allowed indirect comparison of sensitivities and specificities to be 
made, in addition to allowing DORs to be calculated, which is one of the advantages 
of the Bayesian method adopted.  To produce results that are comparable to those 
from standard methods of meta-analysis we did not use informative priors. 
In addition to providing sensitivity and specificity estimates we also reported 
the DOR results.  Some meta-analysis models can only provide the DOR estimate 
and therefore we included this measure for comparability.  A strength of the DOR is 
that it is a mathematically robust measure, (like the standard odds ratio) and 
represents diagnostic accuracy as a single value.  However, a disadvantage is that 
different combinations of sensitivity and specificity values can lead to the same DOR 
value.  
To be included studies had to meet specific inclusion criteria. The validity of 
indirect comparisons does depend upon assumptions regarding the characteristics of 
the included studies; however the indirect method is formally performing the 
comparison that users of the report are likely to make when assessing the pooled 
results for the individual tests. As such this method of indirect comparisons serves 
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an important purpose and reaffirms the lack of certainty about which test is indeed 
the best.   
There are many potential sources of bias in primary diagnostic accuracy 
studies. Despite the huge volume of literature, no good quality studies were found 
providing a positive response to all questions on the modified QUADAS checklist. 
Based on limited evidence, of tests reported by higher quality studies, including the 
three tests that were considered to merit further evaluation, estimates of sensitivity 
and specificity varied according to study quality.   
There is no universally agreed optimal reference standard for the diagnosis of 
OAG, although progressive structural optic neuropathy has been proposed as the 
best possible reference standard.69,70  In this review either of two reference standards 
were considered.  There was no obvious pattern in terms of the sensitivity and 
specificity of the tests in the seven studies18,34,40,43,44,48,58 that used the first and best 
reference standard of OAG confirmed on longitudinal follow-up compared with the 
remainder that used ophthalmologist-diagnosed OAG.  Although the latter is 
suboptimal compared with the former, it is the accepted reference standard in 
clinical practice.  However establishing a reference standard in glaucoma is 
problematic, as in some people optic disc damage precedes visual field loss while in 
others the reverse is the case.   
The accuracy of a test may vary according to the population in which it is 
performed.  Samples with higher prevalence often arise through preferential 
inclusion of suspect cases, which shifts the disease severity to include more moderate 
and severe disease, and since it is easier to differentiate between severely diseased 
and non-diseased people, a test would be expected to report improved (apparent) 
sensitivity and specificity.  Therefore studies with a significantly higher prevalence 
than expected in a screening population should be interpreted with this limitation in 
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mind.21,28-30,36,39   These studies, including two that met the criteria for higher quality 
studies,30,39 tended to recruit their participants through media advertising rather than 
contacting individuals in a predefined population and can be considered to be more 
representative of screening in higher-risk populations. 
Twenty of the 40 studies included were hospital-based, which  by nature, an 
enriched population, and likely to include a disproportionate number of participants 
with high IOP, and with previous experience of tests, potentially leading to over 
optimistic performance estimates.71-74  The majority of the case-control studies 
identified applied stringent criteria for inclusion such as visual acuity of 6/9, or no 
other ocular disease and as such were highly prone to bias.75  To minimise this 
spectrum bias, case-control studies (n=57) where the participants were considered 
unrepresentative of a case-mix found in a general population where OAG screening 
would be carried out were excluded from the review. 
 In the meta-analysis models for the individual tests, statistical heterogeneity 
was evident across most studies. Empirically, there was no obvious single cause for 
the heterogeneity, but potential contributory factors include differences in 
populations, study design, setting, prevalence and severity of glaucoma within 
studies.  Other factors include differences in reference standard, and in tests included 
within the same category (e.g. different types of perimetry and ophthalmoscopy have 
a large number of variants, potentially leading to heterogeneity in discriminatory 
power across studies reporting those tests), and the extent to which studies were 
affected by other potential biases (e.g. partial and differential verification bias, 




Relatively few studies were identified for each test and it was not possible to perform 
sensitivity analysis based on study design.  The common cutoff chosen for each test 
was the one most frequently reported across the included studies for that test, 
although this may not be the most appropriate.  The majority of the studies were 
poorly reported, an issue that has been highlighted in recent literature.76-79  Only six 
of the 40 studies directly compared two or more tests.  It was not possible to provide 
summary results of studies that directly compared tests because of small numbers.  
Studies not providing sufficient information to allow the calculation of 2 x 2 tables 
were excluded, although they may have contributed information in terms of 
sensitivity and specificity.  
Systematic reviews provide a robust and rigorous evaluation of the available 
evidence, but by their nature as new studies are published the review requires 
updating.  Since the completion of our meta-analysis further studies have been 
published on the performance of the tests included in this review.  These include 
population-based studies in the USA, UK, Hungary, Japan and China.  These studies 
provide additional information on the performance of FDT perimetry alone;80-82  in 
combination with GDx VCC,83  and combined with an IOP measurement84 and data 
on the performance of HRT II in an elderly population in the UK85 and in a 
community screening programme in Japan,86 comparing HRT II with non-mydriatic 
fundus photography.  Although systematic reviews rapidly become out of date, 
which is a limitation, a strength of a systematic review is that the methods are 
transparent and reproducible such that the review can be updated as further data 
become available in the future.  Priorities for future research and optimal study 
designs can also be identified.  
 
Implications for Practice and Recommendations for Research 
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Ideally, a screening test for OAG should be safe, easy to administer and interpret, 
portable, quick, and acceptable to the people who are to be tested, and sufficiently 
valid to distinguish between those who do and do not have OAG. Many potential 
screening tests for glaucoma are available. Of the many candidate tests, no one test or 
group of tests was clearly more accurate.  Based on limited data, relatively poorly 
performing tests, ophthalmoscopy, standard automated perimetry, retinal 
photography, and Goldmann applanation tonometry, were identified.  
 Frequency doubling technology, (C 20-1), Heidelberg Retinal Tomography 
and oculokinetic perimetry were identified as having better diagnostic performance 
than other candidate tests, although these findings were based on poor quality 
evidence.   Further studies should evaluate the most promising tests in directly 
comparative studies in a relevant population. 
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Titles and abstracts screened (n=5918) 
Not relevant (n=5041) 
Full articles screened (n=877) 
Excluded studies (n=831): 
Case-control studies with participants not representative of a 
screening situation or of a glaucoma suspect population 
referred from GP or optometric practice (n=57) 
Failed to meet one or more inclusion criteria in terms of study 
design, participants, index tests, reference standard or 
outcomes reported (n=774) 
Met inclusion criteria (40 studies, 46 publications) 
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1.  Where a study reported two or more tests and they differed in meeting any one 
QUADAS criterion, e.g. one test checked ‘Yes’ and one checked ‘No’, then the ‘No’ 
answer was taken to represent the study for that item.  This applied to the following 
studies for the following items: 
(i) Robin 2005.30  Question 5 was Yes for FDT, No for HRT II, No for SAP. 
(ii) Wang 1998.36  Question 5 was Yes for ophthalmoscopy, Yes for RNFL 
photography, No for SAP, No for GAT.  Question 9 was Yes for RNFL 
photography, No for ophthalmoscopy, No for SAP, No for GAT. 
(iii) Marraffa 1989.44  Question 11 was Yes for Henson, Unclear for the other 
perimetry tests. 
(iv) Spry 2005.46  Questions 5 and 7 were Yes for FDT, No for SAP. 
(v) Harper 1994.52  Questions 5 and 12 were Yes for OKP, No for SAP. 
(vi) Quigley 1980.57  Question 5 was Yes for RNFL, No for optic disc photography. 
 2.  Unclear means insufficient information was provided to determine whether the 
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3. Partial verification bias avoided? 
4. Differential verification bias 
avoided? 
4. Incorporation bias avoided? 
5. Test review bias avoided? 
6. Diagnostic review bias avoided? 
7. Clinical review bias avoided? 
8. Uninterpretable results reported? 
9. Withdrawals explained? 
10. Index test technology current? 
11. Positive result clearly defined? 
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Figure 3 Summary of sensitivity and specificity of tests included in the 


































1.  Number of studies: ophthalmoscopy (n = 5), optic disc photography (n = 6), RNFL 
photography (n = 4), HRT II (n = 3), FDT C-20-1 (n = 3), FDT C-20-5 (n = 5), OKP (n = 




Table 1 Characteristics of the included studies.   
 
 
Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 
Gender Country Time 
period 
Population-based studies (cross-sectional)   
Anton 200416  GAT Ophthalmologists Ophthalmic 
examination 







GAT Ophthalmologists Ophthalmic 
examination 
1938 1511 (55 to 69) N/S Sweden(Dalby 
Population 
Survey) 
1977 - 1978 
Bonomi 200118  GAT Ophthalmologists Follow-up 
confirmation 
5816 4297 eyes of 4297 
people 














1802 3211 eyes of 1620 
people 
63  
(22 to 97) 











303 264 right eyes, 265 




M: 90;  
F: 179 
Canada August 2003 
– February 
2004 
Hollows 196622  GAT Ophthalmologists Ophthalmic 
examination  
4608 4231 55  
(40 to 74) 
Approx:  
M: 3639;  
F: 592 
UK (Rhondda 
Valley Study)  
Summer 
1963 












1992 - 1994 
Katz 199124  SAP threshold N/S Ophthalmic 
examination 





N/S USA (Glaucoma 
Screening Study) 
1981 – 1992 












Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 




GAT Uncertain Ophthalmic 
examination 
1300 1107 (40 to 80+) M: 463;  










FDT C-20-5 N/S Ophthalmic 
examination 
296 251 eyes of 251 
people 
45  
(30 to 65) 









145 145 71 M: 40;  
F: 105 
USA N/S 
Robin 200530  Ophthalmoscopy; 
HRT II; SAP 






704 261 eyes of 261 
people (all tests) 
65 M: 281;  
F: 378 
Australia Nov 2001 
Weih 200137  Ophthalmoscopy  N/S Consensus 
by panel of 
ophthalmolo
gists, based 
on results of 
ophthalmic 
examination  
































259 175 eyes of 175 
people (OKP); 240 





(SD 15.6)   





Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 
Gender Country Time 
period 
Population-based studies (cohort) 
Christoffersen 
199519  
 Patient source: 
general practice 




195  187 57  
(40 to 84) 
























65 M: 374;  
F: 500 
UK N/S 


















214 (SAP);  
357 (GAT) 
[136 (RNFL photo)] 
(40 to 65+) M: 111;  
F: 294 
USA Jul 1991 – 
Feb 1992 
Population-based studies (case-control) 


















249  182 (disc photo); 
228 (SAP); 









Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 
Gender Country Time 
period 
Study  










GAT N/S Follow-up 
confirmation 










eye clinic  
Ophthalmoscopy  Nurses skilled in 




219 188 (21 and 
over) 
N/S USA N/S 
Khong 200142 
Patient source: 
eye clinics  
FDT C-20-5 N/S Ophthalmic 
examination 
228 113 68.5  
(23 to 91) 
M: 104;  
F: 119 








performed by 2nd or 




2631 574 (<65 to 
75+) 














104 182 eyes of 104 
people 
54.3  
(18 to 76) 













258 365 eyes of ? people (<40 to 
>70) 
M: 112;  
F: 144; 
Unknown: 




Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 















FDT C-20 matrix 
SAP: clinic staff 
trained in visual 
field testing;  
FDT: N/S  
Ophthalmic 
examination 
48 48 (both tests) 67.3  
(SD 13.5) 
M: 24;  
F: 24 







Ophthalmoscopy  Optometrists Ophthalmic 
examination 
50 50 eyes of 50 people N/S N/S UK N/S 





RNFL photography N/S Follow-up 
confirmation 
142 132 eyes of 132 
people 
Glaucoma: 




57 (SD 12.7) 








SAP threshold Uncertain Ophthalmic 
examination 
180 180 eyes of 180 
people 
Glaucoma: 
61 (SD 8); 
Normal:  
59 (SD 9) 
N/S Spain N/S 
Damato 198950 
Patient source: 








N/S UK  N/S 
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Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 
























SAP threshold N/S Ophthalmic 
examination 




(28 to 80); 
Normal: 51 
(26 to 75) 












(43 to 85); 
Normal: 
61.5  
(41 to 85) 






FDT C-20-1;  
FDT C-20 full 
threshold   
N/S Ophthalmic 
examination 
1112 208 (FDT C-20-1); 




(13 to 91);  
Normal: 63 
(33 to 94) 
Eligible :Gl
aucoma:  












Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 








M: 118;  





















M: 16; F: 13 
Normal:  





FDT C-20-1 N/S Ophthalmic 
examination 




(35 to 85); 
Normal: 46 
(18 to 81) 
 USA N/S 
Quigley 198057 







RNFL photography  
Ophthalmologists Ophthalmic 
examination 












M: 86;  
F: 89 
        
 




Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 

























Unclear 223 eyes of ? people 
(both tests) 


































N/S UK N/S 
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Study id  Index test(s)  Test(s) carried out 





Analysed Mean age 
(range) 





not stated  




22 43 eyes of 22 people (32 to 75) N/S UK N/S 
 
Notes: 
1. N/S, not stated. 
2. Numbers analysed are people unless otherwise stated. 




Table 2 HSROC analysis: all studies compared with higher quality studies. 
 
 
 Optic disc photography HRT II FDT C-20-5 SAP threshold 


















73 (61 to 83) 89 (50 to 99) 86 (55 to 97) 89 (66 to 98) 78 (19 to 99) 75 (57 to 87) 88 (65 to 97) 80 (55 to 93) 
Higher 
quality 
74 (30 to 95) 82 (45 to 97) 93 (58 to 99) 85 (47 to 97) 72 (26 to 96) 60 (17 to 92) 73 (28 to 95) 64 (22 to 92) 
 
Notes: 
1.  Optic disc photography (all studies n = 6, higher quality studies n = 3); HRT II (all studies n = 3, higher quality studies n = 2); FDT C-20-5 (all 










Table 3 Sensitivity, specificity, DOR and relative DOR at the common cutoff for studies directly comparing tests.  
 
 
Study id Test Common cutoff Sens % (95% CI) Spec % (95% CI) DOR (95% CI) RDOR (95% CI) 
Vitale 200034 SAP supra 3 adjacent points missed 50 (37 to 63) 83 (76 to 88) 5 (3 to 9) 1 
 Optic disc photo VCDR > 0.6 77 (62 to 89) 59 (50 to 67) 5 (2 to 11) 0.99 (0.36 to 2.75) 
Ieong 200355 SAP supra Optometrist judgement 72 (53 to 87) 95 (82 to 99) 46 (9 to 237) 1 
 HRT II Global/one of six segments abnormal 69 (49 to 85) 95 (82 to 99) 39 (8 to 198) 0.85 (0.08 to 8.54) 
Robin 200530 SAP threshold AGIS score ≥ 3 [common cutoff] 63 (38 to 84) 74 (68 to 80) 5 (2 to 13) 1 
  HRT II ≥ 1 borderline or 1 severe abnormality 95 (74 to 100) 81 (75 to 85) 75 (10 to 574) 15.01 (1.57 to 143.82) 
 FDT C-20-5 One abnormal point 84 (60 to 97) 55 (49 to 61) 7 (2 to 23) 1.31 (0.27 to 6.43) 
Spry 200546  SAP threshold GHT outside normal limit and/or p < 0.05 
with the PSD global index in one/ both eyes 
80 (52 to 96) 52 (34 to 69) 4 (1 to 18) 1 
  FDT C-20 matrix 100 (78 to 100) 27 (13 to 46) 12 (1 to 222)  2.83 (0.11 to 72.91) 
Ivers 200123 SAP supra 3 or more points missing 89 (80 to 94) 73 (71 to 74) 20 (10 to 39) 1 
 GAT IOP > 22 mmHg 14 (7 to 23) 98 (97 to 98) 6 (3 to 12) 0.31 (0.12 to 0.78) 
Wang 199836 SAP supra Absolute or relative defects ≥ 17 70 (57 to 80) 67 (59 to 74) 5 (2 to 9) 1 
 GAT IOP > 21 mmHg 28 (17 to 40) 96 (93 to 98) 9 (4 to 19) 1.89 (0.70 to 5.13) 
 
Notes: 
1.  RDOR = Relative DOR= index test DOR/ SAP DOR. 
2.  RDOR calculated as all direct studies had SAP as one of the tests.  Values of RDOR > 1 indicate that the test performed better than SAP in the study and 
values < 1 indicate that the test performed worse than SAP. 
3.  AGIS, Advanced Glaucoma Intervention Study; GHT, Glaucoma Hemifield Test; PSD, Pattern Standard Deviation.  
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HRT II  
(86%, 89%) 
versus 






SAP threshold  
(88%, 80%) 
versus 




75%) versus         
GAT (46%, 95%) 
Optic disc 
photo 
-12 (-46 to 20) 
6 (-7 to 21) 
        
RNFL photo -14 (-50 to 26) 
6 (-7 to 30) 
-2 (-31 to 34) 
-0 (-17 to 24) 
       
HRT II 
 
-24 (-57 to 14)5 
5 (-9 to 30) 
-12 (-38 to 22) 
-1 (-18 to 24) 
-10 (-45 to 25) 
-1 (-25 to 24) 
      
OKP 
 
-20 (-54 to 19) 
4 (-9 to 26) 
-8 (-35 to 27) 
-2 (-18 to 21) 
-6 (-43 to 30) 
-1 (-26 to 22) 
4 (-29 to 38) 
-1 (-26 to 22) 
     
SAP supra -10 (-43 to 20) 
9 (-4 to 22)5 
2 (-23 to 25) 
3 (-13 to 17) 
4 (-31 to 29) 
3 (-21 to 18) 
14 (-18 to 36) 
4 (-21 to 19) 
10 (-24 to 34) 
5 (-18 to 19) 
    
SAP threshold -26 (-58 to 2)4 
14 (-2 to 37)4 
-14 (-38 to 7)5 
8 (-11 to 31) 
-12 (-46 to 12) 
8 (-17 to 32) 
-2 (-34 to 18) 
9 (-18 to 33) 
-6 (-39 to 16) 
10 (-15 to 34) 
-16 (-37 to 5)5 
5 (-12 to 28) 




C-20-1 -30 (-62 to -0)3 
0 (-11 to 18) 
-18 (-42 to 6)5 
-6 (-21 to 12) 
-16 (-50 to 10) 
-5 (-29 to 13) 
-6 (-38 to 17)5 
-4 (-29 to 14) 
-10 (-42 to 14) 
-3 (-26 to 14) 
-20 (-40 to 3)4 
-8 (-22 to 9) 
-4 (-23 to 18) 
-13 (-36 to 6)5 
  
C-20-5 -11 (-49 to 32) 
19 (-2 to 53)4 
1 (-30 to 40) 
12 (-10 to 47) 
3 (-36 to 44) 
12 (-16 to 47) 
12 (-23 to 52) 
13 (-16 to 49) 
9 (-29 to 49) 
14 (-13 to 49) 
-1 (-29 to 38) 
10 (-12 to 45) 
15 (-11 to 53) 
5 (-23 to 41) 
19 (-10 to 57)5 




15 (-22 to 47) 
-0 (-12 to 7) 
27 (-4 to 53)4 
-6 (-21 to 3)5 
29 (-10 to 57) 
-6 (-30 to 4) 
39 (3 to 64)3 
-5 (-30 to 5) 
35 (-2 to 62)4 
-4 (-26 to 5) 
25 (-2 to 50)4 
-9 (-22 to 0)4 
41 (14 to 64)3 
-14 (-37 to -1)3 
45 (17 to 68)3 
-0 (-18 to 8) 
26 (-16 to 57) 
-19 (-53 to -0)3 
Notes: 
1. In the column headings the summary sensitivity and specificity values from the HSROC meta-analysis models are shown after the name of the test. 
2. Test A (column) versus test B (row) = A – B.  For each comparison, within each cell, the top row is the median difference in sensitivity (95% CrI) and the  
bottom row is the median difference in specificity (95% CrI). 
3. Statistically significant difference at 5% significance level. 
4. Statistically significant difference at 10% significance level. 
5. Statistically significant difference at 20% significance level. 
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Appendix 1 Summary of sensitivity, specificity and DOR for tests included in the HSROC meta-analysis models.   
 
Test Number of 
studies 
Common cutoff Sensitivity %      
(95% CrI) 
Specificity %      
(95% CrI) 
DOR                     
(95% CrI) 
Ophthalmoscopy 5  VCDR ≥ 0.7  60 (34 to 82) 94 (76 to 99) 26 (6 to 110) 
Optic disc photography 6 VCDR ≥ 0.6  73 (61 to 83) 89 (50 to 99) 22 (3 to 148) 
RNFL photography 4 Diffuse and/or localised defect  75 (46 to 92) 88 (53 to 98) 23 (4 to 124) 
HRT II 3 ≥ 1 borderline or outside normal limits 86 (55 to 97) 89 (66 to 98) 51 (11 to 246) 
FDT 
C-20-1 3 1 abnormal point 92 (65 to 99) 94 (73 to 99) 181 (25 to 2139) 
C-20-5 5 1 abnormal point 78 (19 to 99) 75 (57 to 87) 10 (0.7 to 249) 
OKP 4 1 abnormal point 86 (29 to 100) 90 (79 to 96) 58 (4 to 1585) 
SAP suprathreshold 9 ≥ 3 points missing 71 (51 to 86) 85 (73 to 93) 14 (6 to 34) 
SAP threshold 5 AGIS score ≥ 3  88 (65 to 97) 80 (55 to 93) 30 (6 to 159) 
GAT 9 IOP > 21 mmHg 46 (22 to 71) 95 (89 to 97) 15 (4 to 49) 
Notes: 
1. The common cutoff was considered to also include the following cutoffs: Ophthalmoscopy (discs graded as normal or suspicious, subjective criteria); 
Optic disc photography (VCDR ≥ 0.7, normal/glaucomatous disc based on majority opinion of observers); RNFL photography (NFL l ost); HRT II (global 
or 1 of the 6 segments flagged abnormal); OKP (1 or more points missing, if ≥ 1 chart numbers consistently made the black stimulus disappea r); SAP 
suprathreshold (≥ 17 relative or absolute defects and/or cluster of 8 in any one quadrant, ≥ 4 abnormal points in any single quadrant, sufficient points to 
drop the indicator into the suspicious zone or below, 3 abnormal adjacent points, ≥ 1 missed point, optometrist judg ement, at least 1 absolute defect 
associated with 1 relative defect or 3 adjacent relative defects or 4 non-adjacent relative defects or sure nasal step); SAP threshold (cross meridional, GHT 
abnormal/borderline, LDA 59 points, mirror image method, GHT outside normal limit and/or PSD p<0.05 in on or both eyes); GAT (IOP ≥ 21 mmHg, 
IOP 21-22 mmHG, IOP > 22 mmHG).  
2. NFL, nerve fibre layer, AGIS, Advanced Glaucoma Intervention Study, GHT, Glaucoma Hemifield Test, LDA, Logistic Discriminant Analysis. 
